

Table of Contents

The Copyright Page	14
Legal Disclaimer & Terms of Use	14
1. Errors and Omissions Disclaimer	14
2. Intellectual Property (IP) Protection	15
3. No Legal or Consultant-Client Relationship	15
4. Jurisdiction and Applicability	15
5. Acceptance of Terms	16
Chapter 1: The 510(k) Pathway — Legal Basis, Scope & Strategic Context	18
1.1 History and Statutory Authority	18
1.1.1 Origins: The Medical Device Amendments of 1976	18
1.1.2 Key Legislation and Regulatory Milestones	19
1.1.3 The Governing Regulation: 21 CFR Part 807 Subpart E	20
1.2 The Three Submission Types: Traditional, Abbreviated, and Special 510(k)	20
1.2.1 The Traditional 510(k)	20
1.2.2 The Abbreviated 510(k)	21
1.2.3 The Special 510(k)	21
1.3 510(k) vs. De Novo vs. PMA — Choosing the Right Pathway	22
1.3.1 The Premarket Approval (PMA) Pathway	22
1.3.2 The De Novo Classification Request	23
1.3.3 Pathway Comparison Matrix	23
1.3.4 Strategic Pathway Selection Considerations	24
1.4 The Device Classification System: Class I, II, III and Product Codes	24
1.4.1 Class I Devices — General Controls	25
1.4.2 Class II Devices — Special Controls	25
1.4.3 Class III Devices — Premarket Approval	25
1.4.4 The FDA Product Classification Database and Product Codes	26
1.5 Who Must Submit — Domestic Manufacturers, Importers, Repackagers, and Contract Manufacturers	27
1.5.1 Domestic Manufacturers	27
1.5.2 Importers	27
1.5.3 Repackagers and Relabelers	27
1.5.4 Contract Manufacturers	28
1.5.5 Exempt Categories	28
1.6 Current Submission Volumes and the 2026 Review Environment	28

1.6.1 Volume and Clearance Statistics	28
1.6.2 The 2026 Regulatory Environment.....	29
1.7 Chapter Summary and What Lies Ahead	30
Key Terms and Definitions.....	31
Key Regulatory References for Chapter 1	31
Chapter 2: Device Classification & Predicate Selection.....	34
2.1 Navigating the FDA Product Classification Database (21 CFR Parts 862–892).....	34
2.1.1 Structure of the Classification Regulations (21 CFR Parts 862–892).....	34
2.1.2 How to Use the Product Classification Database	35
2.1.3 Classification Panels and Review Divisions.....	36
2.2 Understanding Regulation Numbers, Product Codes, and Device Classes	37
2.2.1 The Regulation Number	37
2.2.2 The Product Code.....	37
2.2.3 The Device Class.....	38
2.3 Principles of Predicate Device Selection — The Same Intended Use Requirement.....	39
2.3.1 The Legal Foundation: What Makes a Device a Valid Predicate.....	39
2.3.2 The Same Intended Use Requirement — The Threshold Test.....	40
2.3.3 Technological Characteristics — Same vs. Different.....	40
2.4 FDA's September 2023 Draft Guidance on Predicate Selection Best Practices.....	41
2.4.1 Background and Policy Context.....	41
2.4.2 The Four Best Practices — Detailed Analysis	42
Best Practice 1: Select a Predicate Cleared Using Well-Established Methods	42
Best Practice 2: Select a Predicate That Meets or Exceeds Current Safety and Performance Benchmarks.....	43
Best Practice 3: Select a Predicate Without Unmitigated Use-Related or Design-Related Safety Issues.....	43
Best Practice 4: Select a Predicate Without an Associated Design-Related Recall.....	44
2.4.3 Transparency Recommendations: Disclosing the Predicate Selection Analysis	45
2.5 Single vs. Split Predicates — Risks and Justification Strategies.....	46
2.5.1 The Single Predicate Approach	46
2.5.2 The Split Predicate Approach — Definition and Mechanics	46
2.5.3 Risks of the Split Predicate Approach.....	47
2.5.4 Justification Strategy for Split Predicates	47
2.6 Predicate Lineage and the "Predicate Creep" Problem	48
2.6.1 What is Predicate Creep?	48
2.6.2 Why Predicate Lineage Matters in 2026	49

2.6.3 Conducting a Predicate Lineage Analysis	50
2.7 When to Consider De Novo as an Alternative Pathway	51
2.7.1 De Novo Eligibility — The Core Requirements	51
2.7.2 The De Novo Advantage — Why It Is Often Underutilized.....	51
2.7.3 Decision Triggers: When the Analysis Should Shift from 510(k) to De Novo	52
2.7.4 De Novo Strategy — Key Elements of a Successful Request	53
2.8 Chapter Summary and Transition to Substantial Equivalence Analysis	54
Key Terms and Definitions.....	55
Key Regulatory References for Chapter 2	56
Chapter 3: Substantial Equivalence — The Core Legal Standard	59
3.1 Statutory Definition and Practical Interpretation.....	59
3.1.1 The Legal Text	59
3.1.2 What "Substantially Equivalent" Does Not Mean	60
3.2 The FDA 510(k) Substantial Equivalence Decision Flowchart	60
3.2.1 Decision 1 — Is the Predicate Legally Marketed?	60
3.2.2 Decision 2 — Does the New Device Have the Same Intended Use as the Predicate?	61
3.2.3 Decision 3 — Does the New Device Have the Same Technological Characteristics?	61
3.2.4 Decision 4 — Do the Different Technological Characteristics Raise Different Questions of Safety and Effectiveness?	62
3.2.5 Decision 5 — Is the Performance Data Adequate to Demonstrate Equivalence?.....	62
3.3 Building the Two-Part SE Argument: Intended Use and Technological Characteristics	63
3.3.1 Structuring the Intended Use Argument.....	63
3.3.2 Structuring the Technological Characteristics Argument	64
3.4 Performance Data Strategies to Bridge Technological Differences	65
3.4.1 Bench Performance Testing.....	65
3.4.2 Biocompatibility Testing (ISO 10993)	66
3.4.3 When Clinical Data is Required	66
3.5 SE Failure Modes — NSE Determinations and Their Root Causes	68
3.5.1 Root Causes of NSE Determinations	68
3.5.2 NSE Appeals and Options	69
3.6 The SE Standard in the 2026 Regulatory Environment	69
3.6.1 AI/ML-Enabled Devices and the SE Framework	69
3.6.2 Heightened Scrutiny of Technological Differences in 2026.....	70
3.6.3 SE and the September 2023 Predicate Best Practices Guidance	70
3.7 Chapter Summary	71
Key Terms — Chapter 3	71

Key Regulatory References — Chapter 3	72
Chapter 4: Submission Architecture & the eSTAR Format	75
4.1 21 CFR 807.87 — The Mandatory Content Requirements	75
4.1.1 The §807.87 Required Elements — Annotated	75
4.2 The Three Submission Types — Format Implications	77
4.3 The eSTAR Program — Mandatory Electronic Submission Since October 2023	78
4.3.1 What eSTAR Is and How It Works	78
4.3.2 eSTAR Template Versions — 2026 Status	78
4.3.3 Practical Workflow Challenges with eSTAR	79
4.4 The CDRH Portal — Submission and Tracking	80
4.4.1 Portal Registration and Account Management	80
4.4.2 The Submission Workflow — From Upload to Acceptance	80
4.5 Structuring the Technical File — Content Organization Best Practices	81
4.5.1 The Submission Narrative	81
4.5.2 The Device Description Section	82
4.5.3 The 510(k) Summary vs. the 510(k) Statement	82
4.6 Document Management, Version Control, and Internal Review	83
4.6.1 Document Naming Conventions	83
4.6.2 Internal Review Gate	84
4.7 2026 eSTAR Updates — QMSR Alignment and RWE Integration	85
4.7.1 QMSR Alignment	85
4.7.2 Real-World Evidence (RWE) Integration	85
4.8 Chapter Summary and Transition to Chapter 5	86
Key Terms — Chapter 4	86
Key Regulatory References — Chapter 4	87
Chapter 5: Indications for Use & Device Description	90
5.1 The Indications for Use Statement — Legal Framework and Purpose	90
5.1.1 Regulatory Basis	90
5.1.2 Intended Use vs. Indications for Use — A Critical Distinction	91
5.2 Drafting the Indications for Use Statement — Precision and Scope	92
5.2.1 The Anatomy of a Well-Drafted IFU Statement	92
5.2.2 The Scope Problem: Too Broad vs. Too Narrow	92
5.3 Form FDA 3881 — Completion Requirements in the eSTAR Environment	93
5.3.1 Integrated Form in eSTAR	93
5.3.2 The Rx/OTC Designation — Regulatory Implications	94
5.3.3 Consistency Across All Submission Sections	94

5.4 Special IFU Scenarios — Combination Products, Accessories, Software-Only Devices, and Multi-Function Claims	95
5.4.1 Combination Products.....	95
5.4.2 Accessories.....	95
5.4.3 Software as a Medical Device (SaMD).....	96
5.4.4 Multi-Function Devices	96
5.5 The Device Description — What It Must Contain and Why It Matters	97
5.5.1 Purpose and Legal Basis	97
5.5.2 Required Elements of the Device Description.....	97
5.5.3 Device Description for Software-Containing Devices.....	99
5.6 Internal Consistency — The IFU-Device Description-Labeling Triangle	100
5.7 IFU and Device Description Master Review Checklist	101
5.8 Chapter Summary	102
Chapter 6: Substantial Equivalence Comparison Table.....	105
6.1 The Purpose and Legal Basis of the SE Comparison Table	105
6.1.1 Regulatory Basis	105
6.1.2 What the Table Must Accomplish	106
6.2 Table Architecture — Structure and Format	106
6.2.1 Required Column Structure.....	106
6.2.2 Row Organization — Logical Grouping of Characteristics	107
6.3 Classifying Characteristics as Same or Different	108
6.3.1 The "Same" Determination — What It Requires.....	108
6.3.2 The "Different" Determination — The Most Important Rows in the Table.....	109
6.4 Writing Strong Rationale Statements for Technological Differences	110
6.4.1 The Four Types of Acceptable Rationale	110
6.4.2 Rationale Statements That Will Fail Reviewer Scrutiny.....	111
6.5 Worked Examples — Complete SE Comparison Table Excerpts.....	111
6.5.1 Example A — Device with Primarily Same Characteristics (Glucose Monitor)	111
6.5.2 Example B — Device with Multiple Technological Differences (Infusion Pump with Software).....	114
6.6 Special Comparison Table Scenarios	117
6.6.1 Split Predicate Tables	117
6.6.2 Reference Devices	117
6.6.3 AI/ML Characteristics	118
6.6.4 Cybersecurity Characteristics.....	118
6.7 SE Comparison Table Master Review Checklist.....	119

6.8 Chapter Summary	121
Key Terms — Chapters 5 & 6.....	121
Key Regulatory References — Chapters 5 & 6	122
Chapter 7: Performance Testing — Bench, Animal & Clinical Data.....	125
7.1 The Governing Framework — Risk-Based Testing and FDA-Recognized Standards	125
7.1.1 The Least Burdensome Principle.....	125
7.1.2 FDA-Recognized Consensus Standards.....	126
7.2 Non-Clinical Bench Performance Testing	126
7.2.1 Mechanical Performance Testing	127
7.2.2 Electrical Safety Testing	127
7.2.3 Electromagnetic Compatibility (EMC) Testing	129
7.2.4 Sterilization Validation.....	129
7.2.5 Shelf Life Testing.....	130
7.3 Biocompatibility Testing — ISO 10993 Framework and Current FDA Expectations	131
7.3.1 The Regulatory Framework.....	131
7.3.2 Contact Classification — The Foundation of Biocompatibility Planning	132
7.3.3 The Biocompatibility Endpoints — What Must Be Evaluated	132
7.3.4 Chemical Characterization First — The Modern FDA Approach	134
7.3.5 Biocompatibility for Devices with Same Materials as Predicate	134
7.4 Animal Studies — When Required and How to Design Them	135
7.4.1 When Animal Studies Are Indicated.....	135
7.4.2 Design Principles for Submittable Animal Studies	135
7.5 Clinical Data — When Required and How to Structure the Evidence	136
7.5.1 The September 2023 Draft Guidance on Clinical Data	136
7.5.2 Structuring Clinical Data for 510(k)	137
7.5.3 Foreign Clinical Data.....	137
7.5.4 Real-World Evidence in 510(k) Submissions	137
7.6 Performance Testing Planning Framework.....	138
7.7 Chapter Summary	139
Key Terms — Chapter 7	140
Key Regulatory References — Chapter 7	141
Chapter 8: Software, SaMD & Cybersecurity Documentation	143
8.1 Determining Whether Software Constitutes a Device Function	143
8.1.1 The Regulatory Scope of Device Software Functions.....	143
8.2 Software Documentation Requirements — The Risk-Based Documentation Level.....	144
8.2.1 The 2023 Device Software Functions Guidance Framework.....	144

8.2.2 Documentation Level Determination	145
8.2.3 Basic Documentation — Required Elements	145
8.2.4 Enhanced Documentation — Additional Required Elements	146
8.3 Software as a Medical Device (SaMD) — Specific Requirements	146
8.3.1 The IMDRF SaMD Framework	146
8.3.2 AI/ML-Enabled SaMD — 2026 Requirements	147
8.4 Cybersecurity Documentation — Section 524B and the June 2025 Final Guidance	148
8.4.1 Who Is a Cyber Device	148
8.4.2 The Twelve Required Cybersecurity Documents	148
8.4.3 The Secure Product Development Framework (SPDF)	150
8.4.4 The Software Bill of Materials (SBOM)	150
8.4.5 Cybersecurity and the SE Determination	150
8.5 Computer Software Assurance (CSA) — The 2025 Replacement for CSV	151
8.5.1 What CSA Means for Quality System Software	151
8.6 IEC 62304 — Software Lifecycle Requirements for Medical Device Software	152
8.7 Software Documentation Master Review Checklist	152
8.8 Chapter Summary	154
Key Terms — Chapter 8	155
Key Regulatory References — Chapter 8	156
Chapter 9: Labeling Requirements	159
9.1 The Legal Definition and Scope of Labeling	159
9.1.1 What "Labeling" Means Under Federal Law	159
9.1.2 The Label vs. Labeling Distinction	160
9.2 Mandatory Labeling Content — 21 CFR Part 801	160
9.2.1 General Labeling Requirements — Subpart A	160
9.2.2 Instructions for Use (IFU) — Content Requirements	162
9.3 Prescription vs. Over-the-Counter Device Labeling	163
9.3.1 Prescription (Rx) Device Labeling — 21 CFR 801.109	163
9.3.2 Over-the-Counter (OTC) Device Labeling	163
9.4 IVD Labeling — 21 CFR Part 809	164
9.4.1 Required IVD Label Information	164
9.4.2 IVD Package Insert — 21 CFR 809.10(b)	164
9.5 Unique Device Identification (UDI) Requirements	166
9.5.1 The UDI System — Overview and Legal Basis	166
9.5.2 UDI Format and Presentation Requirements	166
9.5.3 UDI Applicability by Device Class — 2026 Status	167

9.5.4 GUDID — Global Unique Device Identification Database	167
9.6 Symbols in Device Labeling	168
9.7 Electronic Labeling (eIFU) for Prescription Devices	168
9.8 The 21 CFR 807.97 Misbranding Prohibition.....	169
9.9 Labeling for the 510(k) Submission — What to Submit	169
9.10 Labeling Master Review Checklist	170
9.11 Chapter Summary	172
Key Terms — Chapter 9	172
Key Regulatory References — Chapter 9	173
Chapter 10: Human Factors & Usability Engineering.....	176
10.1 Regulatory Basis and Governing Standards	176
10.1.1 FDA's Human Factors Guidance Framework	176
10.1.2 IEC 62366-1 — The International Usability Engineering Standard.....	177
10.1.3 AI/ML-Specific HFE Requirements — January 2025 Draft Guidance	177
10.2 When Human Factors Documentation Is Required in a 510(k)	178
10.2.1 The Decision Framework.....	178
10.2.2 Specific Device Types with Heightened FDA HFE Scrutiny	178
10.3 The Human Factors Engineering Process — Six Core Activities	179
10.4 User Population Analysis and Use Environment Assessment	180
10.4.1 Defining Intended Users.....	180
10.4.2 Use Environment Assessment.....	181
10.5 Critical Task Identification and Task Analysis.....	181
10.5.1 Defining a Critical Task	181
10.5.2 Methods for Use Error Identification	182
10.6 Formative Usability Studies — Design and Documentation	182
10.6.1 Study Design Considerations for Formative Evaluation	182
10.6.2 Documenting Formative Studies for 510(k)	183
10.7 Summative (Validation) Usability Studies — The Definitive Test	183
10.7.1 Purpose and Standards	183
10.7.2 Sample Size — FDA's Minimum of 15 Per User Group.....	184
10.7.3 Simulated Use Environment.....	184
10.7.4 Data Collection, Root Cause Analysis, and Remediation.....	185
10.8 The HFE Report — Structure and 510(k) Submission Requirements	185
10.9 Human Factors for OTC and Home-Use Devices	186
10.10 Human Factors and the SE Comparison Table	187
10.11 Human Factors Documentation Master Review Checklist	188

10.12 Chapter Summary	190
Key Terms — Chapter 10.....	191
Key Regulatory References — Chapter 10	192
Chapter 11: Risk Management Documentation.....	194
11.1 The Governing Standard — ISO 14971:2019	194
11.1.1 Overview and FDA Recognition.....	194
11.1.2 What Changed in ISO 14971:2019 vs. the 2007 Edition.....	195
11.2 The ISO 14971 Risk Management Process — Seven Steps	196
11.2.1 Step 1 — Establish the Risk Management Plan.....	196
11.2.2 Step 2 — Hazard Identification.....	196
11.2.3 Step 3 — Risk Estimation.....	198
11.2.4 Step 4 — Risk Evaluation and Risk Acceptability.....	198
11.2.5 Step 5 — Risk Control.....	199
11.2.6 Step 6 — Residual Risk Evaluation and Overall Residual Risk	200
11.2.7 Step 7 — Risk Management Report and Post-Production Activities.....	200
11.3 The Risk Management File — Structure and Contents	201
11.3.1 Required Contents of the Risk Management File.....	201
11.4 What Must Be Submitted to FDA vs. Retained in the DHF.....	202
11.5 Risk Management for Technological Differences — The SE Bridge.....	203
11.6 Software Risk — Device Hazard Analysis.....	204
11.6.1 Cybersecurity Risk Integration	205
11.7 Use-Related Risk — Integration with Human Factors	205
11.8 Benefit-Risk Analysis — ISO 14971:2019 Requirement	206
11.9 Risk Management Documentation Review Checklist.....	206
11.10 Chapter Summary	208
Key Terms — Chapter 11.....	209
Key Regulatory References — Chapter 11	210
Chapter 12: Quality Management System (QMS) & QMSR Alignment.....	213
12.1 The QMSR — What Changed and What Remained the Same	213
12.1.1 The Legal Foundation	213
12.1.2 What the QMSR Adds Beyond ISO 13485	214
12.1.3 Risk Management in the QMSR — A Fundamental Shift	215
12.2 Design Controls Under QMSR — ISO 13485 Clause 7.3.....	215
12.2.1 Design and Development Planning — ISO 13485 Clause 7.3.2.....	216
12.2.2 Design Inputs and Outputs — ISO 13485 Clauses 7.3.3 and 7.3.4.....	216
12.2.3 Design Verification and Validation — ISO 13485 Clauses 7.3.6 and 7.3.7	216

12.2.4 Design Transfer and Change Control — ISO 13485 Clauses 7.3.8 and 7.3.9	217
12.3 QMSR-Specific Documentation for 510(k) Submissions	218
12.3.1 Design History File vs. Device Design File	218
12.3.2 Quality Management System Information for Special 510(k)	218
12.4 MDSAP — International Harmonization and QMSR Alignment.....	219
12.5 Gap Analysis Framework — Transitioning from QSR to QMSR	219
12.6 The New Inspection Program — Compliance Program 7382.850.....	220
12.7 QMSR Readiness and QMS Alignment Checklist for 510(k) Submissions	221
12.8 Chapter Summary	223
Key Terms — Chapter 12.....	224
Key Regulatory References — Chapter 12	225
Chapter 13: The Refuse to Accept (RTA) Checklist & Pre-Submission Strategy	227
13.1 The RTA Policy — Legal Basis, Purpose, and Timeline.....	227
13.1.1 Legal and Regulatory Basis.....	227
13.1.2 Purpose and Operational Rationale	228
13.1.3 The 15-Day Administrative Review Clock.....	228
13.2 The RTA Checklist — Section-by-Section Analysis.....	229
Section 1 — Submission Format and Administrative Information.....	229
Section 2 — Device and Classification Information	230
Section 3 — Indications for Use	230
Sections 4–7 — Summary/Statement, Device Description, Standards, and SE Discussion	231
Sections 8–12 — Performance Testing Summaries.....	231
Section 13 — Labeling.....	232
13.3 The eSTAR Technical Screening — Differences from Traditional RTA	233
13.4 Internal RTA Mock Review — Process and Protocol	233
13.5 Pre-Submission (Q-Sub) Program — The Strategic Foundation.....	234
13.5.1 The Updated Q-Sub Guidance — May 2025	234
13.5.2 Q-Sub Types — When to Use Each.....	235
13.6 The Pre-Submission Package — What to Include for Maximum Value.....	236
13.6.1 Recommended Pre-Sub Package Contents	236
13.6.2 What FDA Will and Will Not Do in a Pre-Sub	237
13.7 Strategic Use of Q-Subs in the 2026 Environment.....	237
13.8 User Fees — Current Schedule and Planning Implications	238
13.9 Chapter Summary	239
Key Terms — Chapter 13.....	240
Key Regulatory References — Chapter 13	240

Chapter 14: The FDA Review Process — Substantive Review to Decision	243
14.1 Review Pathway Assignment and Lead Reviewer Identification	243
14.1.1 CDRH Routing and Division Assignment.....	243
14.1.2 Third-Party Review — An Alternative Pathway	244
14.2 The MDUFA Review Clock — FDA Days Explained	244
14.2.1 What Are FDA Days?	244
14.2.2 The 90-Day Goal vs. Real-World Timeline	245
14.3 The Substantive Review — Stages and Communication	246
14.3.1 The Day 60 Substantive Interaction (SI)	246
14.3.2 Interactive Review — Managing Real-Time Communications	246
14.4 The Additional Information (AI) Request — Anatomy and Response Strategy	247
14.4.1 Anatomy of an AI Request Letter	247
14.4.2 The 180-Day Response Deadline — No Exceptions	247
14.4.3 Interpreting AI Deficiency Items — Identifying the Underlying Concern.....	248
14.4.4 Structuring the AI Response.....	249
14.5 SE Decision — Clearance, NSE, and the Decision Letter	250
14.5.1 The Substantially Equivalent (SE) Determination.....	250
14.5.2 The Not Substantially Equivalent (NSE) Determination	250
14.6 Appeals and Dispute Resolution	251
14.6.1 Supervisory Review (Informal Appeal).....	251
14.6.2 Formal Dispute Resolution — 21 CFR Part 16 and Section 517A.....	252
14.6.3 513(g) Request for Information.....	252
14.7 Managing the Review in the 2026 Environment.....	252
14.8 Chapter Summary	253
Key Terms — Chapter 14.....	254
Key Regulatory References — Chapter 14	255
Chapter 15: Post-Clearance Obligations, Device Changes & Lifecycle Management.....	257
15.1 Establishment Registration and Device Listing.....	257
15.1.1 Annual Establishment Registration — 21 CFR Part 807	257
15.1.2 Device Listing — 21 CFR Part 807.....	258
15.2 Medical Device Reporting (MDR) — 21 CFR Part 803.....	258
15.2.1 MDR Regulatory Framework	258
15.2.2 MDR Reporting Timelines	259
15.2.3 eMDR — Electronic Submission Requirement.....	260
15.3 Field Safety Corrective Actions and Recalls — 21 CFR Part 806.....	260
15.3.1 Regulatory Framework for Corrections and Removals.....	260

15.3.2 Recall Classification	261
15.3.3 Field Safety Corrective Action (FSCA) Strategy.....	261
15.4 Post-Market Surveillance Strategy	262
15.4.1 PMS Data Sources	262
15.4.2 PMS Plan and PMS Report	262
15.5 UDI/GUDID Database Maintenance.....	263
15.5.1 Events Requiring GUDID Updates	263
15.5.2 Consequences of GUDID Non-Compliance	263
15.6 When a Device Change Requires a New 510(k) — The Change Guidance Framework	264
15.6.1 The 2017 Guidance: Deciding When to Submit a 510(k) for a Change to an Existing Device.....	264
15.6.2 The Cumulative Change Problem.....	266
15.7 Software Change Decision-Making — The 2017 Software Change Guidance	267
15.7.1 The Software Change Decision Framework	267
15.7.2 When Both Guidance Documents Apply.....	268
15.8 Predetermined Change Control Plans (PCCPs) for AI/ML Devices	268
15.8.1 What a PCCP Authorizes	268
15.8.2 PCCP Operational Workflow.....	268
15.9 Post-Clearance Inspection Readiness.....	269
15.9.1 What FDA Inspects Post-Clearance	269
15.9.2 Preparing for Inspection.....	270
15.10 International Pathway Leveraging — Using 510(k) Clearance for Global Market Access	270
15.10.1 EU MDR Pathway.....	270
15.10.2 Health Canada (Canada).....	271
15.10.3 TGA (Australia)	271
15.10.4 PMDA (Japan).....	272
15.11 Post-Clearance Compliance Program Master Checklist	272
15.12 Chapter Summary and Final Guidance for the Lifecycle-Oriented Regulatory Team.....	274
Key Terms — Chapter 15.....	275
Key Regulatory References — Chapter 15	276
Appendices.....	278
Strategic Regulatory Framework for Medical Device Clearances: A Comprehensive Analysis of the 510(k) Pathway and Modernized Submission Architectures (2023–2026).....	278
Modernized Submission Pathways and the Strategic Use of Regulatory Controls	278
Table 1: Comparative Analysis of 510(k) Submission Pathways in 2026.....	278
Appendix A: Detailed Criteria for the FDA 510(k) Refuse to Accept (RTA) Policy	279

Table 2: Technical and Administrative Components of the RTA Checklist.....	280
Appendix B: Technical Architecture and Compliance Logic of the eSTAR Submission Template	281
Table 3: Structural Components and Mandatory Sections of the eSTAR Template (v6.1+)	281
Appendix C: Strategic Workflow for Predicate Device Search and Selection.....	282
Table 4: Step-by-Step Predicate Search and Analysis Workflow	283
Appendix D: Narrative and Technical Construction of the Substantial Equivalence (SE) Comparison Table	284
Table 5: Mandatory Comparison Fields and Justification Criteria.....	284
Appendix E: Strategic Management of the Q-Submission Program and Pre-Submission Request Letters	285
Table 6: Essential Components of a Q-Submission Request Package	285
Appendix F: Comprehensive Compendium of Key FDA Guidance Documents (2023–2026)	286
Table 7: Landmark Regulatory References and Guidance Documents (2023–2026)	286
Appendix G: Glossary of Regulatory and Administrative Terms in the 2026 Environment.....	288
Appendix H: Decision Flowcharts for 510(k) Pathway Selection and Change Management	288
Table 8: Strategic Decision Logic for Device Modifications	288
Strategic Synthesis and Practical Recommendations for Industry Professionals.....	289

Copyright © 2026 by NextGenMedTech

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law.

NextGenMedTech

First Edition: April 2026

Disclaimer: This book is designed to provide general information regarding the US FDA 510(k) submission process. While every effort has been made to ensure the accuracy of the information at the time of publication, regulatory requirements are subject to change. The information contained herein is provided "as is" without warranty of any kind. The author and NextGenMedTech are not responsible for any errors or omissions, or for the results obtained from the use of this information. This publication is sold with the understanding that the author is not engaged in rendering legal or professional regulatory services. If professional assistance is required, the services of a competent professional should be sought.

Trademark Notice: All trademarks, service marks, trade names, and logos appearing in this book are the property of their respective owners. The use of "FDA," "USFDA," and other government terms is for educational and descriptive purposes only and does not imply endorsement by the United States Government.

Legal Disclaimer & Terms of Use

1. Errors and Omissions Disclaimer

The information presented in this book is intended to provide general guidance on medical device regulatory processes, including but not limited to submissions under the U.S. Food and Drug Administration (FDA) framework, ISO standards, and other applicable regulations.

While every effort has been made to ensure the accuracy and completeness of the content, **NextGenMedTech makes no representations or warranties, express or implied,** regarding the accuracy, reliability, or completeness of the information provided.

Regulatory requirements are subject to change, and interpretations may vary depending on specific circumstances, device classification, and regulatory authority expectations. Therefore, this book should be considered a **guidance resource only and not a guarantee of regulatory approval, clearance, or compliance.**

NextGenMedTech shall not be held liable for any direct, indirect, incidental, or consequential damages arising from the use or reliance on the information contained in this book.

2. Intellectual Property (IP) Protection

All content included in this book, including but not limited to frameworks, methodologies, templates, checklists, workflows, graphics, and proprietary systems, is the intellectual property of **NextGenMedTech**, unless otherwise stated.

Specifically, the “**6-Step 510(k) Pipeline**”, associated templates, and structured methodologies are the **exclusive intellectual property of NextGenMedTech**.

No part of this publication may be:

- Reproduced
- Distributed
- Transmitted
- Stored in a retrieval system
- Used for commercial training, consulting, or reselling

without prior written permission or a valid licensing agreement from NextGenMedTech.

Unauthorized use of this material may result in legal action under applicable intellectual property laws.

3. No Legal or Consultant-Client Relationship

The content provided in this book is intended **solely for educational and informational purposes**.

Nothing in this publication shall be construed as:

- Legal advice
- Regulatory approval strategy tailored to a specific product
- Formation of a consultant-client, advisory, or professional relationship

A formal consultant-client relationship with NextGenMedTech is established **only upon execution of a written agreement or engagement letter** that clearly defines the scope of services, responsibilities, and liabilities.

Readers are strongly encouraged to seek **qualified legal counsel, regulatory professionals, or authorized representatives** for advice specific to their device, jurisdiction, and regulatory pathway.

4. Jurisdiction and Applicability

This book primarily references regulatory frameworks such as the **U.S. FDA**, ISO standards, and global medical device regulations. Applicability may vary based on country-specific regulatory requirements, including but not limited to EU MDR, CDSCO (India), and other national authorities.

Users of this content are responsible for ensuring compliance with **all applicable local and international regulations**.

5. Acceptance of Terms

By accessing, reading, or using this book, the reader acknowledges and agrees to the terms outlined in this section.

A TECHNICAL GUIDE TO

U.S. FDA 510(k) SUBMISSIONS

2026 Edition

CHAPTER 1

The 510(k) Pathway — Legal Basis, Scope & Strategic Context

*Prepared for Medical Device Manufacturers, Regulatory Affairs Professionals,
and Innovation-Driven MedTech Teams Preparing for U.S. Market Entry*

Current as of April 2026 | Based on FDA CDRH Guidance

Chapter 1: The 510(k) Pathway — Legal Basis, Scope & Strategic Context

The U.S. Food and Drug Administration's 510(k) premarket notification process is the primary regulatory gateway through which most medical devices reach the American market. Understanding its legal foundations, strategic scope, and operational mechanics is not merely academic — it is a prerequisite for any manufacturer, regulatory affairs professional, or innovator intending to commercialize a medical device in the United States. This chapter establishes the foundational framework upon which every subsequent chapter in this guide is built.

From its origins in the Medical Device Amendments of 1976 to the complex, digitized submission environment of 2026, the 510(k) pathway has evolved considerably — yet its core premise remains unchanged: a device may be marketed in the U.S. without a full clinical trial program, provided the submitter can demonstrate to FDA's satisfaction that the device is substantially equivalent to a legally marketed predicate device. This principle — at once elegant and demanding — defines the strategic landscape for every 510(k) submission.

1.1 History and Statutory Authority

1.1.1 Origins: The Medical Device Amendments of 1976

Prior to 1976, the United States had no comprehensive framework for regulating medical devices as a distinct product category. Devices were regulated sporadically under the broader provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938, primarily through misbranding and adulteration provisions that were ill-suited to the technical realities of medical hardware and diagnostic instruments. A series of public health failures in the late 1960s and early 1970s — most notably the Dalkon Shield intrauterine device, which caused severe harm to thousands of women — catalyzed congressional action.

The Medical Device Amendments of 1976 (Pub. L. 94-295) represented a landmark legislative achievement. Signed into law by President Ford on May 28, 1976, the Amendments created the foundational architecture for modern medical device regulation in the United States. They established a tiered classification system based on risk, created distinct regulatory pathways for different device classes, and granted the FDA authority to require premarket review for higher-risk devices. Crucially, they also introduced the 510(k) premarket notification

mechanism under Section 510(k) of the FD&C Act — a provision that would prove to be the most-used regulatory pathway in the history of medical device oversight.

The 510(k) number itself derives directly from the section of the FD&C Act that established the requirement. Any person intending to introduce a device into interstate commerce must notify the FDA at least 90 days before doing so, if that device was not in commercial distribution before May 28, 1976 (the "preamendment" date). This notification — the 510(k) submission — initiates the review process through which FDA determines whether the new device is substantially equivalent to a predicate.

1.1.2 Key Legislation and Regulatory Milestones

The 1976 Amendments were not the last word on device regulation. A succession of laws have refined, expanded, and modernized the 510(k) framework:

Year	Legislation / Action	Impact on 510(k)
1976	Medical Device Amendments	Created the 510(k) pathway, device classification system (Class I/II/III), and substantial equivalence standard.
1990	Safe Medical Devices Act (SMDA)	Strengthened postmarket surveillance requirements; enhanced FDA authority to require performance standards.
1997	Food and Drug Administration Modernization Act (FDAMA)	Introduced the Abbreviated 510(k) pathway; enabled use of recognized consensus standards; created third-party review program.
2002	Medical Device User Fee and Modernization Act (MDUFMA)	Established user fees for 510(k) submissions; set performance goals for FDA review timelines.
2012	FDA Safety and Innovation Act (FDASIA)	Strengthened CDRH oversight; directed FDA to issue guidance on 510(k) program improvements.
2016	21st Century Cures Act	Supported digital health and software as a Medical Device (SaMD) provisions; encouraged breakthrough device designation.
2022	FDA Omnibus Reform Act (FORA)	Introduced new cybersecurity requirements (Section 524B) for "cyber devices"; now fully in effect.

2026	QMSR (Final Rule, eff. Feb. 2)	Replaced QSR with ISO 13485-aligned Quality Management System Regulation, reshaping quality documentation in submissions.
------	--------------------------------	---

1.1.3 The Governing Regulation: 21 CFR Part 807 Subpart E

The implementing regulation for 510(k) submissions is found at Title 21 of the Code of Federal Regulations (21 CFR), Part 807, Subpart E. This subpart — covering sections 807.81 through 807.100 — establishes the mandatory requirements for when a 510(k) must be submitted (§807.81), what the submission must contain (§807.87), and the special provisions applicable to contact lens solutions and other specific device categories (§807.92–807.97).

Section 807.87 is the practitioner's primary reference. It enumerates the required elements of a premarket notification, including the device name, establishment registration number, device classification, performance standards, intended use statement, comparison to predicate devices, and performance data. Compliance with §807.87 forms the backbone of every section in this guide.

FDA's implementing guidance — most notably "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]" — provides the operational interpretation of these statutory and regulatory requirements. This guidance, along with a constellation of device-specific and topic-specific guidances issued by CDRH, shapes how submissions are prepared and reviewed in practice.

1.2 The Three Submission Types: Traditional, Abbreviated, and Special 510(k)

Within the 510(k) framework, FDA recognizes three distinct submission types, each suited to different scenarios. Selecting the appropriate type is an early strategic decision with consequences for submission structure, the type of supporting data required, and the overall complexity of the application.

1.2.1 The Traditional 510(k)

The Traditional 510(k) is the standard, comprehensive submission pathway. It requires the submitter to provide all information necessary to support a determination of substantial equivalence, including a full device description, intended use statement, comparison to a named predicate device, and all performance data — bench, biocompatibility, software, clinical, and other testing as applicable.

The Traditional 510(k) is the default pathway when neither the Abbreviated nor the Special pathway criteria are met. It is also the appropriate choice when no applicable FDA-recognized consensus standard or device-specific guidance document covers the full scope of the new device's intended use and technological characteristics. For novel devices or devices with significant technological differences from their predicate, the Traditional pathway is almost always required.

Traditional 510(k) submissions tend to be the most resource-intensive, but they offer the greatest flexibility in how substantial equivalence is argued and supported. There is no prescribed format for the performance testing section, for instance — the submitter constructs the evidentiary package appropriate to the device and its risk profile.

1.2.2 The Abbreviated 510(k)

Introduced under FDAMA 1997 and governed by FDA's guidance on the Abbreviated 510(k) program, this pathway allows manufacturers to streamline the performance data section of their submission by relying on one or more of the following:

- FDA-recognized consensus standards (e.g., ISO, ASTM, IEC standards listed in FDA's Standards Database)
- FDA guidance documents that define the scientific and technical requirements for a specific device type
- Special controls established for a device classification under 21 CFR

Rather than providing the full test data in the submission itself, the Abbreviated 510(k) submitter can provide a declaration of conformity to the relevant standard or guidance, supported by summary reports demonstrating compliance. This can significantly reduce the volume of documentation in the submission, but it does not reduce the underlying testing burden — all testing must still be performed; the submission simply presents it in a more condensed format.

It is a common misconception that the Abbreviated pathway is always easier or faster. In many cases, demonstrating full conformity to a consensus standard is as demanding as providing the full test data. The Abbreviated 510(k) is most advantageous when an applicable standard exists, the device design closely conforms to that standard, and the testing has already been completed to meet international market requirements.

1.2.3 The Special 510(k)

The Special 510(k) pathway is available only to manufacturers who are modifying their own previously cleared device. It is not available for new entrants or for modifications to a

competitor's device. The rationale is that the manufacturer already has an established relationship with FDA, a cleared device on record, and a functioning Design Control process under which the modification was developed.

The Special 510(k) is particularly well-suited to:

- Minor design modifications that do not change the intended use
- Changes to materials, dimensions, or processing methods within validated parameters
- Software updates that do not alter the fundamental operating principle of the device

The submission relies heavily on the manufacturer's own Design Control documentation — design verification and validation (V&V) summaries — rather than complete new performance testing. FDA's review of a Special 510(k) is typically faster, with a target review time of 30 days. However, FDA may convert a Special 510(k) to a Traditional 510(k) if the reviewer determines that the changes are more substantial than represented.

The decision framework for when a device change requires a new 510(k) (versus a design change that can be managed internally) is governed by FDA's guidance "Deciding When to Submit a 510(k) for a Change to an Existing Device" and is addressed in detail in Chapter 15 of this guide.

Practical Tip: Choosing Your Submission Type

Begin your submission strategy by asking three questions: (1) Does FDA have a recognized standard or guidance document that covers all key aspects of my device? If yes, consider Abbreviated. (2) Am I modifying my own cleared device, and is the change confined to design, not intended use? If yes, consider Special. (3) Neither of the above? Default to Traditional. When in doubt, the Pre-Submission (Q-Sub) program (covered in Chapter 13) provides an opportunity to confirm your pathway choice with the relevant FDA reviewer before committing resources.

1.3 510(k) vs. De Novo vs. PMA — Choosing the Right Pathway

Understanding the 510(k) pathway in isolation is insufficient. A sophisticated regulatory strategy requires a clear understanding of when the 510(k) is the appropriate pathway, and when De Novo or Premarket Approval (PMA) should be considered instead. Making the wrong pathway choice at the outset can result in months or years of lost time.

1.3.1 The Premarket Approval (PMA) Pathway

PMA is the most stringent device regulatory pathway and is required for Class III devices — those for which substantial equivalence to a predicate cannot be established and for which general and special controls alone are insufficient to provide reasonable assurance of safety and effectiveness. PMA requires independent, valid scientific evidence — typically including randomized controlled clinical trials — to demonstrate safety and effectiveness.

PMA applications are substantially more resource-intensive than 510(k) submissions: they typically take two to four years to prepare, cost millions of dollars in testing and clinical study expenses, and require an average FDA review time of 180 days (with typical total timelines of 12–24 months including supplemental interactions). Examples of PMA devices include implantable cardioverter defibrillators, cochlear implants, and high-risk in vitro diagnostic assays for life-threatening conditions.

The 510(k) pathway becomes unavailable for PMA-class devices once FDA determines that a device has no valid predicate and that the risks it presents are not adequately addressed by general and special controls alone. For innovators developing breakthrough technologies in previously unaddressed indications, PMA may be the mandatory path.

1.3.2 The De Novo Classification Request

De Novo is the regulatory pathway for novel, low-to-moderate-risk devices that have no valid predicate — and therefore cannot be cleared through the 510(k) process — but do not pose the degree of risk that would warrant PMA. De Novo was created by FDAMA 1997 and significantly expanded by the 21st Century Cures Act (2016). It is, in essence, a petition for the FDA to create a new device classification, complete with special controls, into which the requesting device (and future similar devices) can be placed.

A successful De Novo creates a new classified device type. The device that received De Novo authorization then becomes available as a predicate for future 510(k) submitters. This is a critical structural feature of the U.S. regulatory system: De Novo does not simply clear a single device — it establishes the legal and scientific framework for an entire product category.

De Novo requests are appropriate when a manufacturer can demonstrate that its device is low-to-moderate risk and can be adequately controlled through specific performance standards and labeling requirements (special controls), but cannot point to a legally marketed predicate with the same intended use. The pathway typically takes 12–18 months and requires detailed performance testing, risk analysis, and proposed special controls.

1.3.3 Pathway Comparison Matrix

Feature	510(k)	De Novo	PMA
Device Risk Class	Class I / II	New Class I or II	Class III
Predicate Required?	Yes	No	No
Clinical Trial Required?	Rarely	Sometimes	Usually
Avg. FDA Review Time	~90 days	12–18 months	180 days (review only)
Total Timeline	6–18 months	18–30 months	3–7 years
Cost (Approx.)	\$50K–\$500K+	\$300K–\$2M+	\$5M–\$50M+
Creates New Predicate?	No	Yes	No
User Fee (FY2025)	\$24,335 / \$6,084*	\$23,080 / \$5,770*	\$526,186 / \$131,547*

*Standard fee / Small Business fee. Fees updated annually October 1.

1.3.4 Strategic Pathway Selection Considerations

The choice of regulatory pathway is one of the highest-stakes decisions in a medical device company's regulatory strategy. A number of factors should be systematically evaluated:

1. Predicate availability: Can you identify a legally marketed device with the same intended use? If not, 510(k) is unavailable. Consider De Novo if risk is moderate or PMA if high.
2. Risk profile: What is the potential harm to patients if the device malfunctions? Higher risk generally implies a higher regulatory bar and may shift the pathway to PMA regardless of predicate availability.
3. Speed-to-market: 510(k) offers the fastest route if a strong predicate exists. PMA is the slowest. De Novo is intermediate.
4. Competitive dynamics: De Novo creates a new classification that competitors can then use as a 510(k) predicate. If establishing a market-defining standard is strategically valuable, this can outweigh the longer timeline.
5. Breakthrough Device Designation: For devices addressing life-threatening or irreversibly debilitating conditions, Breakthrough Device Designation (available for all three pathways) can accelerate FDA review through dedicated reviewer interaction, priority review, and rolling submissions.

1.4 The Device Classification System: Class I, II, III and Product Codes

Central to every 510(k) strategy is an accurate determination of the subject device's regulatory classification. FDA's classification system assigns medical devices to one of three classes based on their risk profile and the regulatory controls necessary to provide reasonable assurance of safety and effectiveness.

1.4.1 Class I Devices — General Controls

Class I devices are considered the lowest-risk category. They are subject to general controls under Section 501, 502, 510, 516, 518, 519, and 520 of the FD&C Act — including establishment registration, device listing, Quality Management System requirements, labeling requirements, Medical Device Reporting (MDR), and prohibition against adulteration and misbranding. The vast majority of Class I devices are exempt from 510(k) requirements, meaning they do not need premarket notification before marketing, provided they remain within the limitations of the applicable exemption (found in the .9 section of each device classification regulation).

Examples of Class I devices include: elastic bandages, examination gloves, handheld surgical instruments, and manual stethoscopes. While Class I devices are generally low-risk, exemption is not a universal rule — some Class I devices are not 510(k)-exempt and do require a premarket notification. Verification of exemption status in the FDA Product Classification Database is always required before assuming a 510(k) is unnecessary.

1.4.2 Class II Devices — Special Controls

Class II represents the heart of the 510(k) landscape. These are moderate-risk devices for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness, but for which sufficient information exists to establish special controls — such as performance standards, postmarket surveillance requirements, patient registries, special labeling requirements, and guidelines — that, together with general controls, can provide such assurance.

The overwhelming majority of 510(k) submissions — and virtually all cleared 510(k)s — involve Class II devices. Examples span an enormous range: diagnostic imaging equipment, powered wheelchairs, infusion pumps, contact lenses, glucose monitors, ECG machines, and tens of thousands of other device types. FDA's product codes for Class II devices number in the thousands.

1.4.3 Class III Devices — Premarket Approval

Class III devices are the highest-risk category, representing devices that support or sustain human life, are substantially important in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. These devices generally require PMA unless they have a legally marketed predicate from before 1976 (preamendment devices) or have been reclassified to a lower class through a rulemaking process.

Some Class III devices do have 510(k) predicates — particularly those that entered the market before the PMA requirement was fully implemented or that were cleared under predecessor classification schemes. However, FDA has been progressively tightening the availability of Class III 510(k) clearances. A manufacturer who identifies a Class III predicate should carefully evaluate whether FDA has since required PMA for that device type, as the regulatory landscape in this space has evolved substantially.

1.4.4 The FDA Product Classification Database and Product Codes

Every FDA-regulated device is assigned a three-letter product code that identifies its specific device type within the classification system. These codes, managed by CDRH's Product Classification database (accessible at [fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm)), are the regulatory DNA of every device and determine:

- The device's classification (Class I, II, or III)
- The applicable regulation number (e.g., 21 CFR 880.5860 for a particular monitoring device)
- Whether the device is 510(k)-exempt
- Any applicable special controls or recognized performance standards
- The review panel responsible for evaluating submissions in that product category

Correctly identifying the product code for a new device is not always straightforward. A single product can potentially be classified under multiple product codes depending on its intended use, technology, and the specific claims being made. Where ambiguity exists, a 513(g) Request for Information to FDA (a formal pathway to obtain the agency's classification opinion) or a Pre-Submission meeting can resolve the question before a 510(k) is filed. Misclassification is a significant source of RTA deficiencies and substantive review delays.

Key Regulatory Reference: Finding Product Codes

The FDA's Product Classification database is available at:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm>. Search by device name, regulation number, or product code. The 510(k) database (accessible at the same portal)

allows you to search cleared devices by product code, providing a searchable repository of potential predicates.

1.5 Who Must Submit — Domestic Manufacturers, Importers, Repackagers, and Contract Manufacturers

One of the most practically important, and frequently misunderstood, aspects of the 510(k) requirement is determining which parties are legally required to submit. The FD&C Act and 21 CFR Part 807 define this obligation by reference to the action being taken — introducing a device to interstate commerce — rather than the identity of the party.

1.5.1 Domestic Manufacturers

A domestic manufacturer who introduces a device to the U.S. market under their own specification is the paradigm case for 510(k) submission obligation. This encompasses finished device manufacturers — companies that design, manufacture, and market devices under their own name and specifications. Accessories intended to be sold to end users are treated as finished devices for 510(k) purposes; manufacturers of components sold to other manufacturers for incorporation into a finished device, however, are generally not required to submit.

1.5.2 Importers

Foreign-manufactured devices imported into the U.S. require a 510(k) submitted by the U.S. importer, the foreign manufacturer, or their authorized representative. The importer of record bears primary responsibility for ensuring that a valid clearance exists for the device before it enters U.S. commerce. It is not sufficient to rely on regulatory approvals from other jurisdictions (CE marking, PMDA approval, TGA clearance) as a substitute for 510(k) clearance — these are independent regulatory determinations under different legal standards.

1.5.3 Repackagers and Relabelers

A repackager or relabeler who significantly changes the labeling of a device or repackages it in a manner that affects safety (e.g., changing sterility assurances, altering indications) may need to submit their own 510(k). Minor repackaging — for example, adding a "distributed by" label without changing any specifications, indications, or warnings — generally does not

require a new 510(k). The legal standard is whether the repackaging or relabeling constitutes a "significant change" to the device as defined by 21 CFR 807.81(a)(3).

1.5.4 Contract Manufacturers

Contract manufacturers — firms that manufacture a device to another company's specifications under contract — are generally not required to submit a 510(k), because they do not introduce the device into commerce on their own behalf. The specification holder (the company whose design is being manufactured) is the party responsible for the 510(k). This distinction is important in complex supply chains where manufacturing may be outsourced while regulatory ownership resides with the design firm.

1.5.5 Exempt Categories

Several categories of devices are exempt from 510(k) requirements and do not require premarket notification even if they are being introduced to the U.S. market for the first time:

- Class I devices that are listed as 510(k)-exempt in their applicable classification regulation (and do not exceed the limitations of the exemption)
- Devices that were legally in commercial distribution before May 28, 1976 (preamendment devices) and have not been significantly changed or modified
- Custom devices manufactured for a named patient under the custom device exemption of Section 520(b)
- Certain humanitarian use devices under the HDE pathway
- Devices approved under PMA (which have their own change supplement requirements, not 510(k))

Determination of exempt status must be made affirmatively — it is not safe to assume exemption without consulting the relevant classification regulation and the FDA's current exemption determinations for the specific product code. Changes to an exempt device can lift the exemption and require a 510(k) submission.

1.6 Current Submission Volumes and the 2026 Review Environment

Contextualizing the current 510(k) landscape requires understanding both the scale of the program and the specific environmental factors shaping submission strategy in 2026.

1.6.1 Volume and Clearance Statistics

The 510(k) program handles an enormous volume of activity. In recent fiscal years, FDA has received and acted upon more than 3,000 clearance decisions annually — approximately 3,326 clearances in FY2023, 3,107 in FY2024, and 3,238 in FY2025. Total submissions (including those that are withdrawn or not cleared) number in the range of 4,500 to 5,000 per year. To put this in operational terms, CDRH must render approximately 15 clearance decisions per business day simply to keep pace with incoming submissions.

This throughput reality has significant implications for submission quality. Reviewers are working under time pressure, and a submission that requires extensive clarification or generates numerous Additional Information (AI) requests consumes disproportionate reviewer resources. High-quality, complete, and clearly organized submissions are not merely good practice — they are, structurally, the most effective way to achieve timely clearance.

1.6.2 The 2026 Regulatory Environment

The 510(k) review environment in 2026 is characterized by several intersecting dynamics that every submitter must understand:

FDA Workforce Dynamics: CDRH has navigated significant organizational change in 2025, including workforce reductions across the broader agency and leadership transitions. While many device reviewers were subsequently restored, reviewer bandwidth remains stretched and administrative support functions have been reduced. This has created longer average response times for informal reviewer guidance and Q-Sub feedback. The implication for submitters is clear: formal, documented interactions through official channels (Q-Subs, written responses) are more important than ever. Submissions that rely on informal pre-submission alignment with reviewers carry greater risk in the current environment.

Increased Scrutiny of Submissions: In the context of stretched resources, FDA reviewers are increasingly reliant on well-prepared, self-evidently complete submissions. There is reduced capacity for the reviewer to seek out information that should have been in the submission. Incomplete submissions are more likely to generate RTA findings or substantive information requests that add months to the clearance timeline. The 2026 environment rewards meticulous pre-submission preparation.

Deregulatory Signals in Digital Health: Under Commissioner Makary, FDA has signaled a shift in regulatory philosophy in certain areas — particularly digital health. The January 2026 revised guidance on Clinical Decision Support (CDS) software significantly narrowed the

scope of software regulated as a medical device, with an enforcement discretion policy for certain CDS functions. Manufacturers of software products should carefully assess whether their device is still subject to 510(k) requirements under the updated framework.

QMSR Transition: The Quality Management System Regulation (QMSR), effective February 2, 2026, replaces the decades-old Quality System Regulation (QSR) with an ISO 13485:2016-aligned framework. This is the most significant change to the U.S. device quality system requirements in 30 years. Its implications for 510(k) submissions — particularly the design control documentation and verification/validation evidence included in or referenced by the submission — are addressed in detail in Chapter 12.

1.7 Chapter Summary and What Lies Ahead

This chapter has established the legal and strategic foundations of the 510(k) pathway. The key principles to carry forward through the remainder of this guide are:

- The 510(k) is a premarket notification, not a premarket approval. The legal standard is substantial equivalence — not independent proof of safety and effectiveness.
- Three submission types exist (Traditional, Abbreviated, Special), each suited to different scenarios. Selection of the appropriate type is an early strategic decision.
- The 510(k) exists within a broader pathway ecosystem (De Novo, PMA) and the choice between them is consequential. Pathway misidentification is costly.
- Correct device classification and product code identification are prerequisites for every submission and directly determine the regulatory requirements that apply.
- The obligation to submit is tied to the action (introducing a device to commerce) not just the manufacturer's identity — importers, repackagers, and relabelers may also be required to submit.
- The 2026 regulatory environment rewards exceptionally well-prepared, complete submissions. Informality, ambiguity, and incomplete documentation are more costly than ever.

Chapter 2 moves from these foundations to one of the most consequential decisions in any 510(k) strategy: the selection of the predicate device. As subsequent chapters will demonstrate, the predicate is not merely a regulatory formality — it is the scientific, legal, and strategic anchor upon which the entire substantial equivalence argument is built. Getting predicate selection right is the single most impactful thing a regulatory team can do to improve the probability of a timely, successful clearance.

Key Terms and Definitions

Term	Definition
510(k)	A premarket notification submitted to FDA under Section 510(k) of the FD&C Act to demonstrate that a new device is substantially equivalent to a legally marketed predicate device.
Predicate Device	A legally marketed device to which substantial equivalence is claimed. Must share the same intended use as the subject device.
Substantial Equivalence (SE)	The legal standard for 510(k) clearance: the new device has the same intended use as the predicate and either the same technological characteristics, or different technological characteristics that do not raise new safety/effectiveness questions and the device is at least as safe and effective as the predicate.
CDRH	Center for Devices and Radiological Health — the FDA center responsible for regulating medical devices.
21 CFR Part 807	The Code of Federal Regulations section governing establishment registration, device listing, and 510(k) requirements.
Product Code	A three-letter FDA code identifying a specific device type within the classification system.
PMA	Premarket Approval — the most stringent FDA pathway, required for Class III devices; demands valid scientific evidence (typically clinical trials) of safety and effectiveness.
De Novo	A regulatory classification request for novel low-to-moderate risk devices without a predicate; creates a new device classification and serves as the basis for future 510(k)s.
QMSR	Quality Management System Regulation — the new U.S. device quality system rule effective February 2, 2026, aligned with ISO 13485:2016, replacing the former QSR.
RTA	Refuse to Accept — FDA's administrative screening determination (Day 15) that a submission does not contain the threshold elements required for substantive review.

Key Regulatory References for Chapter 1
